Neurology

Phase II Data in Treatment-Naïve Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Ruxoprubart Demonstrates Best-in-Class Efficacy as Monotherapy

--- Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). Paroxysmal Nocturnal Hemoglobinuria...

Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting

Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data

HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader...

Lundbeck joins forces with Danish Centre for AI Innovation to improve brain health by advancing drug discovery with Gefion AI supercomputer

VALBY, Denmark, May 6, 2025 /PRNewswire/ -- H. Lundbeck A/S is pleased to announce its agreement with the Danish Centre for AI...

Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator (DxA) Partners with Siemens Healthineers to License DxA’s SpeechDx Dataset, Gold-Standard Dataset for Alzheimer’s Speech Biomarkers

error: Content is protected !!